Summary of COVID-19 amiodarone studies

1. Navarese et al., Ion channel inhibition with amiodarone or verapamil in symptomatic hospitalized nonintensive-care COVID-19 patients: The ReCOVery-SIRIO randomized trial

143 patient amiodarone late treatment RCT: 103% higher mortality (p=0.33), 52% higher ventilation (p=0.43), and 30% worse recovery (p=0.19).
RCT 215 hospitalized non-intensive care COVID-19 patients showing no significant difference in clinical improvement with amiodarone or verapamil. The trial, which aimed to assess the effects of ion channel inhibitors on COVID-19 progression, was prematurely terminated due to slow enrollment.
Sep 2022, Cardiology J., https://journals.viamedica.pl/cardiology_journal/article/view/88627, https://c19p.org/navarese